Archives
ALDOB K87 Lactylation Drives Mitochondrial Fission in PH
ALDOB K87 Lactylation Orchestrates Mitochondrial Dynamics and Metabolic Remodeling in Pulmonary Hypertension
Study Background and Research Question
Pulmonary hypertension (PH) is a progressive cardiopulmonary disorder defined by persistent elevation of pulmonary arterial pressure, vascular remodeling, and right ventricular failure. Despite advances in vasodilator-based therapies, long-term prognosis remains poor, largely due to the disease's underlying proliferative and metabolic derangements. In recent years, the centrality of pulmonary artery smooth muscle cell (PASMC) proliferation and metabolic reprogramming—particularly the shift toward aerobic glycolysis—has come into focus. However, the molecular mechanisms linking metabolic cues to vascular cell behavior in PH are not fully elucidated.
The reference study by Yi et al. addresses this gap by investigating how lactate-induced post-translational modifications regulate mitochondrial dynamics and cell proliferation in PH. Specifically, the research focuses on the role of lysine 87 (K87) lactylation of aldolase B (ALDOB), an enzyme central to glycolysis, in orchestrating mitochondrial fission and metabolic rewiring that drive PH pathogenesis.
Key Innovation from the Reference Study
The pivotal innovation of this work is the identification of ALDOB K87 lactylation as a molecular switch that couples increased glycolytic activity with mitochondrial fission in PH PASMCs. Using advanced lactylomic profiling, the researchers demonstrate that hypoxic conditions, which mimic the PH microenvironment, induce robust lactylation at the K87 residue of ALDOB. This post-translational modification enhances glycolytic flux, promoting lactate production and creating a self-reinforcing loop of lactylation signaling.
Crucially, the study reveals a novel mechanism whereby ALDOB K87 lactylation recruits dynamin-related protein 1 (DRP1) to mitochondria. This process is mediated by sentrin/SUMO-specific peptidase 3 (SENP3)-dependent deSUMOylation of DRP1, enabling DRP1-driven mitochondrial fragmentation—a process well known to facilitate cell proliferation and phenotypic switching in vascular disease.
Methods and Experimental Design Insights
The authors employed a combination of state-of-the-art experimental approaches to dissect the role of ALDOB lactylation in PH:
- Lactylome sequencing of PASMCs under hypoxic versus normoxic conditions, enabling the identification of differentially lactylated proteins and sites.
- Validation of findings in rodent models of PH, ensuring clinical and translational relevance. Both genetic and pharmacological manipulations were used to modulate ALDOB lactylation status.
- Functional assays investigating PASMC proliferation, migration, and mitochondrial dynamics (using confocal microscopy and mitochondrial fission markers such as DRP1).
- Site-directed mutagenesis to create lactylation-mimetic and non-lactylatable ALDOB mutants, allowing direct assessment of K87 lactylation's functional role.
- Biochemical assays for glycolytic flux, lactate production, and assessment of Sirtuin 1 (SIRT1) activity as a potential delactylase.
This multifaceted approach provides strong evidence for a causal link between ALDOB K87 lactylation, mitochondrial fission, and the hyperproliferative phenotype of PH PASMCs.
Core Findings and Why They Matter
The research establishes several critical findings:
- Hypoxia-induced ALDOB K87 lactylation amplifies glycolysis, driving further lactate accumulation and reinforcing the lactylation signal.
- Lactylated ALDOB interacts with DRP1 via SENP3-mediated deSUMOylation, promoting mitochondrial fission and PASMC proliferation.
- SIRT1 acts as a regulatory delactylase, with its downregulation in PH sustaining pathogenic ALDOB lactylation.
- Pharmacological or genetic inhibition of ALDOB lactylation attenuates mitochondrial fission and PASMC proliferation in vivo, while lactylation-mimetic mutants exacerbate disease phenotypes.
Together, these findings delineate a lactate–ALDOB–DRP1 axis as a central driver of metabolic and structural remodeling in PH, providing a mechanistic bridge between aberrant metabolism and vascular pathology. This has far-reaching implications for targeting metabolic-epigenetic coupling in vascular diseases beyond PH.
Comparison with Existing Internal Articles
Several recent reviews and experimental protocols provide context for the translational application of these findings:
- The article "ALDOB K87 Lactylation Links Mitochondrial Fission to PH Progression" summarizes the mechanistic cascade elucidated in the reference study and underscores the centrality of the lactate–ALDOB–DRP1 axis in smooth muscle cell proliferation and vascular remodeling.
- Resources such as "Applied Workflows with Murine Recombinant PDGF-BB: Protocols & Innovation" and "Applied Workflows with Murine Recombinant PDGF-BB in Vascular Remodeling" detail experimental protocols for studying cell proliferation and metabolic signaling, directly supporting the type of in vitro and in vivo assays employed in the reference study. These articles emphasize the role of defined growth factors such as murine recombinant PDGF-BB in robustly modeling smooth muscle and connective tissue cell proliferation—key processes affected by ALDOB-driven metabolic reprogramming.
Thus, the reference study complements and extends these internal protocols by pinpointing upstream metabolic regulators that modulate classic growth factor responses in vascular cells.
Limitations and Transferability
While the study offers compelling mechanistic insights, several limitations warrant consideration:
- The primary data are derived from hypoxic PASMCs and rodent PH models; although these are well-validated systems, further validation in human tissues and diverse PH etiologies is necessary.
- Although the study demonstrates that SIRT1 downregulation sustains ALDOB lactylation, the full spectrum of regulatory enzymes and potential off-target effects of pharmacological modulators require broader investigation.
- Therapeutic translation of these findings will depend on the development of specific, safe modulators of protein lactylation and mitochondrial dynamics in vivo.
Nonetheless, the mechanistic framework established here is likely transferable to other contexts characterized by metabolic-epigenetic coupling and pathological cell proliferation, such as fibrosis and certain vascular disorders, given the conserved nature of these pathways.
Protocol Parameters
- Cell proliferation assay setup: PASMCs cultured under hypoxia (1-3% O2) for 24-72 h to induce metabolic reprogramming, with or without specific lactylation modulators.
- Growth factor stimulation: PDGF-BB (e.g., murine recombinant PDGF-BB) at 2-20 ng/ml for 24-48 h to assay mitogen-induced proliferation and metabolic responses, as reported in protocol resources.
- Assessment of mitochondrial fission: Immunostaining for DRP1 localization and confocal imaging of mitochondrial morphology, following treatments that modulate ALDOB lactylation or SIRT1 activity.
- Genetic manipulation: Transfection of PASMCs with ALDOB K87 mutants (lactylation-mimetic or non-lactylatable) to dissect site-specific effects on proliferation and mitochondrial dynamics.
- Metabolic flux analysis: Measurement of lactate production and glycolytic rate using standard biochemical assays, with and without ALDOB or SIRT1 modulators.
Research Support Resources
For researchers modeling vascular cell proliferation and metabolic reprogramming, high-purity growth factors are essential for reproducibility. PDGF-BB, murine recombinant protein (SKU P1048) provides defined mitogenic stimulation for PASMC and connective tissue cell assays, as supported by internal workflow articles. This reagent is validated for dose-dependent proliferation assays with an ED50 below 2 ng/ml and is suitable for research into PDGFR-α and PDGFR-β signaling cascades relevant to PH and metabolic remodeling studies. For detailed protocols and troubleshooting, see linked workflow resources.